发明授权
- 专利标题： Chemical compounds 251
- 专利标题（中）： 化合物251
-
申请号： US13000138申请日： 2009-07-02
-
公开(公告)号： US08901307B2公开(公告)日： 2014-12-02
- 发明人: Leslie Dakin , James Edward Dowling , Michelle Lamb , Jon Read , Xiaolan Zheng
- 申请人： Leslie Dakin , James Edward Dowling , Michelle Lamb , Jon Read , Xiaolan Zheng
- 申请人地址： SE Sodertalje
- 专利权人： AstraZeneca AB
- 当前专利权人： AstraZeneca AB
- 当前专利权人地址： SE Sodertalje
- 国际申请： PCT/GB2009/050773 WO 20090702
- 国际公布： WO2010/001169 WO 20100107
- 主分类号： C07D417/10
- IPC分类号： C07D417/10 ; A61K31/454 ; C07D417/14 ; A61K31/427 ; C07D277/34 ; C07D417/06 ; A61K31/426
摘要：
The invention relates to chemical compounds of formula (I), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of PIM-1 and/or PIM-2, and/or PIM-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of PIM kinase related conditions and diseases, preferably cancer.
公开/授权文献
- US20110218182A1 CHEMICAL COMPOUNDS 251 公开/授权日：2011-09-08